A Randomized Clinical Trial Will Assess Efficacy and Safety of Bicalutamide in Hospitalized Patients With COVID-19
Enrollment in this study is expected to begin in July 2020.
Enrollment in this study is expected to begin in July 2020.
Regulations on telehealth services were rapidly deregulated early into the COVID-19 pandemic, but questions remain about quality of care and patient disparities.
COVID-19 has brought unprecedented stress to society at large and perhaps most of all to frontline healthcare teams in a variety of settings. We spoke to an expert about teamwork during such trying times.
The management of CLL, including delays in work-up and treatment, and modifications to clinical trials, have been implemented across Italy in response to the COVID-19 pandemic.
Patients with cancer and COVID-19 had high rates of hospitalization and/or respiratory illness, particularly among those taking immunotherapy or those older than 65 years.
Patients with cancer are more susceptible to infection with SARS-CoV-2, and patients receiving active anticancer treatment have a poorer prognosis.
The first set of guidelines for providing oncology pharmacy services to cancer patients during the COVID-19 pandemic was recently published.
A recent small study is hypothesis generating and highlights the need for COVID-19-related studies with large cohorts of CLL patients.
There have been some concerns that the immunomodulatory effect of PD-1 blockade may influence the response of patients with cancer to COVID-19.
This fact sheet discusses associations between anticancer therapies and outcomes of COVID-19 among patients with cancer.